Hypertension

September 21, 2022

Deepak Bhatt, MD, MPH, discusses the long-term follow-up data from SYMPLICITY HTN-3 from TCT 2022 and explores the prospect of renal denervation outside of clinical trial settings.

September 07, 2022

A new study from the AHA's Hypertension Scientific Sessions provides an overview of the potential population-level benefit of behavior modification, including adherence to a DASH diet, on CVD events and mortality among patients with stage 1 hypertension.

September 03, 2022

Although the European Society of Cardiology (ESC) Congress 2022 may be over, our editorial team is recapping the most popular new trial data from the ESC’s first in-person conference since 2019. The top 5 trials, which were chosen based on total views per article, includes DELIVER, TIME, AXIOMATIC-SSP, FIDELITY, and DANCAVAS.

August 27, 2022

Our cardiology month in review spotlights the most popular content from the past month. The top content from August 2022 includes new antithrombotic guidance from CHEST, USPSTF recommendation statement on statin use in primary prevention, and coverage of ESC 22, including DELIVER, TIME, and other late-breaking data.

August 26, 2022

Although the Hygia study suggested nighttime dosing could increase the benefit of risk reduction obtained from antihypertensive medications, the TIME study found no significant improvement in risk reduction afforded by nighttime dosing as compared to morning dosing of medication.

August 19, 2022

An analysis of more than 25,000 years of patient data details a U-shaped association between HDL-C levels and cardiovascular risk among adult men with high blood pressure.

August 15, 2022

Results of the HOME BP study suggest a linked smartphone application combined with standard blood pressure monitoring did not result in superior blood pressure reductions than a standard approach.

August 01, 2022

Using data from the 2020 US Census report and recent NHANES survey data, investigators from Massachusetts General Hospital detail expected increases in the prevalence of cardiovascular risk factors and cardiovascular disease among the US population by 2060.

July 30, 2022

Our cardiology month in review spotlights the most popular content from the past month. The top content from July 2022 includes hormone therapy guidance from NAMS, a look at the potential for increased risk of kidney damage with a popular statin, and a recap of upcoming decisions and trials of interest in cardiometabolic from the second half of 2022.

July 04, 2022

Dr. Gregory Weiss provides perspective on a recent study suggesting women with gestational hypertension were at an increased risk of chronic hypertension later in life.